Summary 2-Chlorodeoxyadenosine (2-CDA) is an adenosine deaminase resistant analogue of deoxyadenosine which has shown clinical activity in human hematologic neoplasms. The exact mode of action of this drug remains the subject of investigation. We applied the Differential Staining Cytotoxicity (DiSC) assay to 50 human tumour specimens obtained from patients with a variety of hematologic malignancies to characterise the activity spectrum of 2-CDA. We evaluated the disease-specific activity of al., 1992). The mode of action of this drug remains the subject of investigation, however its ability to kill resting as well as proliferating lymphocytes (Seto et al., 1985; Carson et al., 1983) , toxicity to peripheral blood monocytes (Carrera et al., 1989; Carrera et al., 1990 ) and relative non-cross resistance with other nucleoside analogues in cell lines (Seto et al., 1985; Carrera et al., 1990) has intensified interest in the drugs clinical potential. To characterise the activity spectrum of 2-CDA, we utilised the Differential Staining Cytotoxicity (DiSC) assay in 50 fresh human tumour specimens obtained from patients with a variety of hematologic malignancies. The DiSC assay, originally described by Weisenthal et al. (1983) has previously been shown to correlate with both response and survival in solid and hematologic neoplasms (Tidefelt et al., 1989; Lathan et al., 1990; Bosanquet, 1991; Gazdar et al., 1990 (Bosanquet, 1985) .
2-Chlorodeoxyadenosine is an adenosine deaminase resistant analogue of deoxyadenosine (Carson et al., 1980) which has shown clinical activity in human hematologic neoplasms in Phase I and Phase II clinical trials (Carson et al., 1984; Piro et al., 1988; Piro et al., 1990; Santana et al., 1991) . Very recently two additional clinical trials have been published confirming activity of 2-CDA in acute leukaemias (Santana et al., 1992) and low grade lymphomas (Kay et al., 1992) . The mode of action of this drug remains the subject of investigation, however its ability to kill resting as well as proliferating lymphocytes (Seto et al., 1985; Carson et al., 1983) , toxicity to peripheral blood monocytes (Carrera et al., 1989; Carrera et al., 1990) and relative non-cross resistance with other nucleoside analogues in cell lines (Seto et al., 1985; Carrera et al., 1990) has intensified interest in the drugs clinical potential. To characterise the activity spectrum of 2-CDA, we utilised the Differential Staining Cytotoxicity (DiSC) assay in 50 fresh human tumour specimens obtained from patients with a variety of hematologic malignancies. The DiSC assay, originally described by Weisenthal et al. (1983) has previously been shown to correlate with both response and survival in solid and hematologic neoplasms (Tidefelt et al., 1989; Lathan et al., 1990; Bosanquet, 1991; Gazdar et al., 1990) . Our (Bosanquet, 1985) .
Sample preparation
Fresh human tumour specimens were placed in Roswell Park Memorial Institute-1640 media (Irvine Scientific, Irvine, Ca.) containing 15% heat-inactivated foetal bovine serum or 40% heat-inactivated horse serum (Irvine Scientific, Irvine, Ca.) penicillin (100 IU ml'), streptomycin (100 jig ml'), 2 mM glutamine, and 15 units ml-' preservative-free heparin for transport to the laboratory. Tumour 
Results
A comparison of the mean and median IC50 values and ranges for 2-CDA in each of the disease types tested is provided in Figure 1 . All IC50s were calculated from 5 or 10 point dose response curves, using the median effect method of Chou and Talaly (1987 (Nagourney et al., 1989 ) indicated significant cytotoxicity in a variety of human hematologic neoplasms. This was consistent with the clinical activity originally described in Phase I by Carson et al. (1984) and confirmed in Phase II trials (Piro et al., 1988; Piro et al., 1990; Santana et al., 1991; Santana et al., 1992; Kay et al., 1992) . Despite 2-CDA's activity in several lymphatic neoplasms, initial in vitro studies revealed little or no activity in the B cell neoplasm multiple myeloma (Nagourney et al., 1989) . The current report describes observations from 50 specimens of human hematologic tumours and confirms the lack of in vitro activity for 2-CDA in multiple myeloma. The in vitro activity of 2-CDA in both myeloid and lymphoid neoplasms indicated by relatively similar IC50 ranges suggests potentially broad clinical activity. Avery et al. (1989) described significant activity for 2-CDA in cell lines derived from T, B, and non-T/non-B lineages. The significant degree of variance between cell lines was similar to the interspecimen variability evident in our primary cultures studies. 2-CDA has demonstrated clinical activity in Chronic Lymphocytic Leukemia (Piro et al., 1988) Hairy Cell Leukemia , Acute Leukemia (Santana et al., 1991; Santana et al., 1992) and low grade lymphomas (Kay et al., 1992) . The current report is consistent with these observations. The significant difference observed in vitro between multiple myeloma and other tumour types however, strongly suggests that the clinical activity spectrum does not extend to this neoplasm. We recently reported that the multiple myeloma is significantly more resistant in vitro to ARA C than other hematologic neoplasms as well (Nagourney et al., 1991) . Both 2-CDA and ARA C are substrates for 2-deoxycytidine kinase which could theoretically underlie the observed correlation in this disease. Inadequate sample size of myeloma specimens tested in parallel against both ARA C and 2-CDA in the current study precluded calculation of a myeloma-specific correlation for these two drugs.
We compared the in vitro activity of 2-CDA with that of ARA C, vincristine, nitrogen mustard and doxorubicin to assess cross resistance patterns. Pemble et al. (1987) reported non-cross resistance between ARA C and 2-bromodeoxyadenosine (2-BDA) in human myeloid leukaemia. Similarly, we found no correlation between 2-CDA and ARA C nor between 2-CDA and vincristine or doxorubicin. However, correlation was observed between 2-CDA and the alkylating agent nitrogen mustard. Subset analysis performed upon the relatively 2-CDA-sensitive CLL specimens and highly 2-CDA-resistant multiple myeloma specimens indicated that cross resistance was present in both data sets despite their widely different IC5s'S for 2-CDA. Avery (1989) identified synergy between 2-BDA and AZQ in cell lines in vitro. Of interest, AZQ is believed to act by alkylation (Akhatar et al., 1975) . In preliminary experiments, we have now identified true synergy, by isobologram and computer analysis (Chou & Talalay, 1987) , between 2-CDA and the alkylator nitrogen mustard in 4/4 specimens of CLL. Of interest, this degree of synergy was not observed between 2-CDA and gamma irradiation in which only 1/4 CLL specimens revealed synergy and only at suprapharmacologic concentrations. These observations suggest a relationship between the modes of action or mechanisms of resistance of 2-CDA and the mustard alkylators which may not extend fully to gamma irradiation, i.e. depurination.
1.2
Conceptually, a laboratory assay which assesses the activity of a chemotherapy drug by measuring total cell kill in a largely non-dividing population of cells should be valid and correlate with clinical outcome if (i) the mechanisms of cell kill in vitro are related and proportional to the mechanisms of cell kill in vivo or (ii) the mechanisms of cellular resistance in vitro are related and proportional to the mechanisms of resistance in vivo.
Prior investigations have shown that 2-CDA causes significant cell kill in non dividing populations (Seto et al., 1985; Carson et al., 1983) . Seto et al. reported that exposure to 2-CDA results in activation of poly ADP ribose polymerase with resultant depletion of cellular NAD and subsequent cell death (Seto et al., 1985) . Activation of Poly ADP ribose polymerase has been identified following radiation and alkylator exposure (Berger et al., 1979; Smulson et al., 1977; Berger, 1985) . 2-CDA has also been shown to inhibit DNA polymerases, induce depurination and to result in double-strand DNA breaks (Hentosh et al., 1990; Griffig et al., 1989; Tanabe et al., 1989) . These activities are all associated with the actions of alkylators. The chemical structure of 2-CDA does not suggest a free-radical mechanism as its mode of action nor as a basis for cross resistance with alkylators. However, activation of Poly ADP ribose polymerase, inhibition of DNA polymerases, single or double strand breaks, depurination or as-yet-unrecognised actions could underlie the observed cross resistance pattern. If confirmed, these results suggest novel therapeutic strategies utilising combinations of alkylators and 2-CDA as promising directions for future clinical trials.
In conclusion, this report confirms our original observations utilising the DiSC assay (Nagourney et al., 1989) regarding the in vitro activity spectrum of 2-CDA in primary cultures of human neoplasms. The current report describes in vitro activity for this agent in a variety of human hematologic neoplasms with the distinct exception of multiple myeloma. Within given tumour types inter-specimen variation was also observed. Finally, we have observed significant cross resistance between 2-CDA and nitrogen mustard and preliminary evidence of synergy between these agents. The DiSC assay has previously been shown to correlate with both response and survival in a variety of human neoplasms. In this regard, it may serve as a conduit for newly derived agents to enter clinical testing predicated upon the activity spectra identified in vitro. Since the time of our original in vitro studies with 2-CDA, several clinical trials have established the activity for this drug in many of the neoplasms that we had examined and reported upon in abstract form. At the time of this writing we are unaware of any published data regarding the clinical activity of 2-CDA in multiple myeloma. We await the completion of further clinical trials to allow a prospective assessment of the predictive accuracy of these in vitro observations.
